USA: Long-Term Collaboration Moderna Partners with Thermo Fisher Scientific to Produce Covid-19 Vaccines, Other Medicines
Under a 15-year strategic collaboration agreement signed between Moderna and Thermo Fisher Scientific, both the firms will work together to ensure large-scale manufacturing of Moderna’s Covid-19 vaccine, and other investigational mRNA drugs in the USA.
Cambridge/UK – Moderna and Thermo Fisher Scientific have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax, Moderna’s Covid-19 vaccine, and other investigational mRNA medicines in its pipeline.
Over the past several years, Thermo Fisher has been partnering with Moderna to support its development pipeline with both clinical research and contract manufacturing services. This included the quick scale-up of aseptic fill-finish services and packaging of its COVID-19 vaccine. As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling. In addition, the company will provide inspection, labeling and final packaging services.